【文献解读】ERCC1基因在结肠直肠癌患者中的表达：一项探索性研究
2017/7/15 创新医学网

    

     文章来源：欧尔意 OAE微信号作者：Sofina

    

     原文出处

     Gajjar KK, Yadav DK, Kobawala TP, Trivedi TI, Vora HH, Ghosh NR. ERCC1 expression in patients with colorectal cancer: a pilot study. J Cancer Metastasis Treat 2016;2:471-6.

     DOI:10.20517/2394-4722.2016.52

     摘要

     目的：切除修复交叉互补基因1(ERCC1)在由奥沙利铂治疗引起的DNA损伤修复中起关键作用，并可能导致这些铂类药物在结肠直肠癌(CRC)患者中的抗药性。因此，本次初步研究旨在探讨ERCC1 C/T多态性在密码子118中的作用及其在原发性CRC患者中的免疫反应性。方法：采用PCR-RFLP方法检测ERCC1多态性，并通过免疫组化法来检测50例CRC患者的ERCC1蛋白的表达。结果：与C/C (38%)和/T (10%)基因型相比，ERCC1密码子118 C/T多态性分析报道了C/T (52%)基因型占优势。此外，72%的患者显示阳性的ERCC1蛋白表达。临床病理参数与ERCC1多态性之间无显著的相关性，而ERCC1蛋白表达仅与肿瘤部位(结肠与直肠)显著相关(P = 0.046)。而且，本研究未能证明ERCC1 C118T多态性或蛋白质表达作为CRC患者有用的预后标志物的作用。结论：ERCC1阳性蛋白表达可能是直肠癌患者的有效标志物。然而，需要对更多的CRC患者进行进一步评估，以便更好地了解ERCC1的作用。

     关键词：切除修复交叉互补基因1，奥沙利铂，结肠直肠癌，多态性，蛋白表达。

     enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer (CRC) patients. Hence, the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC. Methods: ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients. Results: ERCC1 codon 118 C/T polymorphism analysis reported the predominance of C/T (52%) genotype as compared to C/C (38%) and T/T (10%) genotypes. Furthermore, 72% of patients showed positive ERCC1 protein expression. Significant correlation was not observed between clinicopathological parameters and ERCC1 polymorphism, while ERCC1 protein expression significantly correlated only with tumor site (colon vs. rectum) (P = 0.046). Further, the present study failed to demonstrate the role of ERCC1 C118T polymorphism or protein expression as useful prognostic markers in CRC patients. Conclusion: ERCC1-positive protein expression may be a useful marker for rectal cancer patients. However, further evaluation in a larger set of CRC patients is required to better understand the role of ERCC1.

     Key words:

    Excision repair cross complementation group 1,oxaliplatin,colorectal cancer,polymorphism,protein expression,PCR-RFLP, immunohistochemistry.

     原文链接

     各位读者可复制此链接到浏览器中打开。

     http://jcmtjournal.com/article/view/1721

     或可点击屏幕左下方“阅读原文”，免费获取全文!

     联系我们

     Journal of Cancer Metastasis and Treatment旨在分享癌症转移与治疗方面的最新研究，为该领域的研究学者和临床医生提供一个国际性学术交流平台。自2015年4月创刊以来，期刊读者遍布全球153个国家和地区，已在线发表文章118篇。诚挚欢迎您投稿!如有任何问题，请联系我们：

     editorialoffice@jcmtjournal.com.

     中文摘要内容由OAE Publishing Inc. 北京办公室负责翻译。中文内容仅供参考，一切内容以英文原版为准。

     本文转载已获OAE 微信号 授权 更多精彩，点击下方“阅读原文”查看。

    http://weixin.100md.com
返回 创新医学网 返回首页 返回百拇医药